

Press Release

SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany

Munich, 2 April 2025

SYNLAB further densifies and optimises its network

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, today sold parts of its activities in Eastern Europe to Medicover Group. This relates to the SYNLAB entities in Croatia, Cyprus, North Macedonia (subject to registration of shareholder change in commercial register), Romania, Slovenia and Turkey. The buyer, Medicover Group, is a European healthcare and diagnostic services company and operates a large number of ambulatory clinics, hospitals, laboratories and blood-collection points.

These divestments align with SYNLAB's overarching strategy to densify its network by focusing on countries that offer attractive strategic perspectives for the Group's further development. Operations in Croatia, Cyprus, North Macedonia, Romania, Slovenia and Turkey accounted for approximately 1.5% of total Group revenue in 2024.

"Through active portfolio management, we continuously review our activities, the strategic perspectives and future growth potential across our markets. As a result, we have decided to sell parts of our operations in our existing portfolio, as we see limited opportunities to further scale up in these geographic regions," said Mathieu Floreani, CEO of the SYNLAB Group.

"Efficient capital deployment is a key element of our Group strategy. In line with this strategy, we enhance performance and optimise our network focusing on densification within key countries while diversifying across markets," added Floreani. "We are thankful for the contribution and dedication of our highly skilled SYNLAB colleagues and are confident they will succeed in their new setup."

-- end --



For more information:

Media contact: Steffi Susan Kim, FTI Consulting	steffi.kim@fticonsulting.com +49 (0) 171 5565 996
Investor contact:	ir@synlab.com

About SYNLAB

- SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 26,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.62 billion in 2024.
- More information can be found on www.synlab.com